Literature DB >> 23380313

BDNF-TrkB signaling and neuroprotection in schizophrenia.

Chirayu D Pandya1, Ammar Kutiyanawalla, Anilkumar Pillai.   

Abstract

Neurotrophins such as brain-derived neurotropic factor (BDNF), play critical role in neuronal survival, synaptic plasticity and cognitive functions. BDNF is known to mediate its action through various intracellular signaling pathways triggered by activation of tyrosine kinase receptor B (TrkB). Evidence from clinical as well pre-clinical studies indicate alterations in BDNF signaling in schizophrenia. Moreover, several antipsychotic drugs have time-dependent effects on BDNF levels in both schizophrenia subjects and animal models of schizophrenia. Given the emerging interest in neuroplasticity in schizophrenia understanding the neuroprotective and cell survival roles of BDNF signaling will enhance our knowledge of its diverse effects, which may lead to more effective treatments for schizophrenia. This article will present an overview of recent findings on the role of BDNF signaling in the pathophysiology and treatment of schizophrenia, with a special focus on its neuroprotective effects.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23380313      PMCID: PMC3565158          DOI: 10.1016/j.ajp.2012.08.010

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  118 in total

1.  Brain-derived neurotrophic factor prevents phencyclidine-induced apoptosis in developing brain by parallel activation of both the ERK and PI-3K/Akt pathways.

Authors:  Yan Xia; Cheng Z Wang; Jie Liu; Noelle C Anastasio; Kenneth M Johnson
Journal:  Neuropharmacology       Date:  2009-11-01       Impact factor: 5.250

2.  Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.

Authors:  Reiji Yoshimura; Nobuhisa Ueda; Hikaru Hori; Atsuko Ikenouchi-Sugita; Wakako Umene-Nakano; Jun Nakamura
Journal:  World J Biol Psychiatry       Date:  2010-03       Impact factor: 4.132

3.  Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.

Authors:  Emmanouil N Rizos; Athanasia Papadopoulou; Efstathios Laskos; Panagiota G Michalopoulou; Anastasia Kastania; Dimitrios Vasilopoulos; Konstantinos Katsafouros; Lefteris Lykouras
Journal:  World J Biol Psychiatry       Date:  2010-03       Impact factor: 4.132

Review 4.  BDNF function and intracellular signaling in neurons.

Authors:  Tadahiro Numakawa; Shingo Suzuki; Emi Kumamaru; Naoki Adachi; Misty Richards; Hiroshi Kunugi
Journal:  Histol Histopathol       Date:  2010-02       Impact factor: 2.303

5.  Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes.

Authors:  Da Chun Chen; Jing Wang; Bo Wang; Sheng Chang Yang; Chong Xi Zhang; You Lan Zheng; Yan Li Li; Ning Wang; Ke Bing Yang; Mei Hong Xiu; Thomas R Kosten; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2009-09-29       Impact factor: 4.530

6.  Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia.

Authors:  Yumiko Ikeda; Noriaki Yahata; Itsuo Ito; Masatoshi Nagano; Tomoko Toyota; Takeo Yoshikawa; Yoshiro Okubo; Hidenori Suzuki
Journal:  Schizophr Res       Date:  2008-03-04       Impact factor: 4.939

7.  Interaction between brain-derived neurotrophic factor Val66Met polymorphism and recent negative stressor in harm avoidance.

Authors:  Seog Ju Kim; Seong-Jin Cho; Ha Min Jang; Jonghan Shin; Pil-Whan Park; Yu Jin Lee; In Hee Cho; Jung-Eun Choi; Heon-Jeong Lee
Journal:  Neuropsychobiology       Date:  2009-11-13       Impact factor: 2.328

8.  Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?

Authors:  Sophia Vinogradov; Melissa Fisher; Christine Holland; Wendy Shelly; Owen Wolkowitz; Synthia H Mellon
Journal:  Biol Psychiatry       Date:  2009-04-15       Impact factor: 13.382

9.  Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics.

Authors:  Mei Hong Xiu; Li Hui; Yu Feng Dang; Tian De Hou; Chong Xi Zhang; You Lan Zheng; Da Chun Chen; Thomas R Kosten; Xiang Yang Zhang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-08-29       Impact factor: 5.067

Review 10.  Cell biology of BDNF and its relevance to schizophrenia.

Authors:  Bai Lu; Keri Martinowich
Journal:  Novartis Found Symp       Date:  2008
View more
  37 in total

1.  BDNF/TrkB Pathway Mediates the Antidepressant-Like Role of H2S in CUMS-Exposed Rats by Inhibition of Hippocampal ER Stress.

Authors:  Le Wei; Li-Yuan Kan; Hai-Ying Zeng; Yi-Yun Tang; Hong-Lin Huang; Ming Xie; Wei Zou; Chun-Yan Wang; Ping Zhang; Xiao-Qing Tang
Journal:  Neuromolecular Med       Date:  2018-04-27       Impact factor: 3.843

2.  Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications.

Authors:  B S Fernandes; J Steiner; M Berk; M L Molendijk; A Gonzalez-Pinto; C W Turck; P Nardin; C-A Gonçalves
Journal:  Mol Psychiatry       Date:  2014-09-30       Impact factor: 15.992

3.  Glucocorticoid regulates TrkB protein levels via c-Cbl dependent ubiquitination: a decrease in c-Cbl mRNA in the prefrontal cortex of suicide subjects.

Authors:  Chirayu Pandya; Ammar Kutiyanawalla; Gustavo Turecki; Anilkumar Pillai
Journal:  Psychoneuroendocrinology       Date:  2014-04-06       Impact factor: 4.905

4.  A Prospective Longitudinal Investigation of Cortical Thickness and Gyrification in Schizophrenia.

Authors:  Eric A Nelson; Nina V Kraguljac; David M White; Ripu D Jindal; Ah L Shin; Adrienne C Lahti
Journal:  Can J Psychiatry       Date:  2020-02-05       Impact factor: 4.356

Review 5.  Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.

Authors:  Meng Xia; Sofya Abazyan; Yan Jouroukhin; Mikhail Pletnikov
Journal:  Schizophr Res       Date:  2014-11-20       Impact factor: 4.939

6.  Modulation of schizophrenia-related genes in the forebrain of adolescent and adult rats exposed to maternal immune activation.

Authors:  Ann M Hemmerle; Rebecca Ahlbrand; Stefanie L Bronson; Kerstin H Lundgren; Neil M Richtand; Kim B Seroogy
Journal:  Schizophr Res       Date:  2015-07-20       Impact factor: 4.939

7.  Altered BDNF is correlated to cognition impairment in schizophrenia patients with tardive dyskinesia.

Authors:  Jing Qin Wu; Da Chun Chen; Yun Long Tan; Shu Ping Tan; Li Hui; Men Han Lv; Jair C Soares; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-07-04       Impact factor: 4.530

8.  Clozapine Improves Memory Impairment and Reduces Aβ Level in the Tg-APPswe/PS1dE9 Mouse Model of Alzheimer's Disease.

Authors:  Yura Choi; Ha Jin Jeong; Quan Feng Liu; Seung Tack Oh; Byung-Soo Koo; Yeni Kim; In-Won Chung; Yong Sik Kim; Songhee Jeon
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

Review 9.  Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions.

Authors:  Matcheri S Keshavan; Urvakhsh Meherwan Mehta; Jaya L Padmanabhan; Jai L Shah
Journal:  Dev Psychopathol       Date:  2015-05

10.  Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia.

Authors:  Maju Mathew Koola; Samir Kumar Praharaj; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2019-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.